Bill McKibben on how we might avert climate change suicide

macleans | April 18, 2019

Thirty years ago, Bill McKibben wrote the first book on climate change for general readers, The End of Nature; it didn’t save the world, but McKibben hasn’t stopped trying. The Vermont-based author and activist’s new volume, Falter: Has the Human Game Begun to Play Itself Out?, explains, in compelling prose and with devastating detail, the magnitude of the risks posed by carbon emissions—and also unregulated genetic engineering and artificial intelligence. He acknowledges the difficulty of making change when vested interests in fossil fuels and big tech have so much leverage. However, McKibben does offer a scintilla of hope, based on the widespread adoption of green technology, the acceptance of regulation, and the power of non-violent protest movements. On the phone from San Diego, where he was fundraising for his grassroots environmental organization, 350.org, McKibben spoke with Maclean’s about how the human species may be able to survive its suicidal impulses. Canada’s got some of the very best climate activists, experts and policy people in the world. And it has a government that’s rhetorically, and in certain respects actually, committed to being a leader on climate change and carbon taxes. But Justin Trudeau said in Houston a couple of years ago, “No country would find 173 billion barrels of oil [in the ground] and just leave them there.” And so, Canada is committed to using up about a third of the remaining carbon budget [we can emit before what] the scientists say is a catastrophe. If Canada’s determined to dig up the oil underneath the oil sands and ship it around the world to people who will burn it, then Canada is inevitably going to be a great source of destruction. We can’t afford to have Canada do that, any more than we can afford to have the U.S. dig up all the coal in the Powder River Basin or have Brazil cut down all the trees in the rainforest.

Spotlight

Our 'Clinical Genetics in Action' series was created in collaboration with the Royal College of Physicians and with Dr Kate Tatton-Brown and Dr Katherine Josephs at St George's Hospital, London. Clinical Genetics is an area of medicine that is rapidly evolving as more genomic tests are developed and we learn more and more about the links between genes and disease. The series showcases some of the many breakthroughs in genomics and how they are changing the lives of patients, whilst also highlighting some of the challenges for healthcare professionals of using genomic technologies.

Spotlight

Our 'Clinical Genetics in Action' series was created in collaboration with the Royal College of Physicians and with Dr Kate Tatton-Brown and Dr Katherine Josephs at St George's Hospital, London. Clinical Genetics is an area of medicine that is rapidly evolving as more genomic tests are developed and we learn more and more about the links between genes and disease. The series showcases some of the many breakthroughs in genomics and how they are changing the lives of patients, whilst also highlighting some of the challenges for healthcare professionals of using genomic technologies.

Related News

INDUSTRIAL IMPACT

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

eTheRNA | February 04, 2022

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA and Merck KGaA, Darmstadt, Germany both recognise the potential for using targeted mRNA therapeutics in an expanded range of diseases. With this collaboration, eTheRNA and Merck KGaA, Darmstadt, Germany will assess the feasibility of using eTheRNA's mRNA and LNP technologies to develop therapeutic vaccination approaches in models of disease. If successful, mRNAs encoding antigens nominated by Merck KGaA, Darmstadt, Germany and directly relevant for human diseases will then be designed and evaluated preclinically. "We are extremely pleased to sign this partnership agreement with Merck KGaA, Darmstadt, Germany, a leading German science and technology company. As two companies committed to innovation and creating patient focused solutions, we are excited about the many advantages such a partnership can offer to improve patient care and address a significant market need". Steven Powell, eTheRNA CEO About eTheRNA immunotherapies eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding.

Read More

CELL AND GENE THERAPY

Terumo Blood and Cell Technologies to Collaborate with CSL Plasma on U.S. FDA Clearance of Plasma Collection Technology

CSL Plasma | March 11, 2022

CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval. The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologies. Additional characteristics of the new Rika system, according to CSL Plasma, will allow for the collection of more plasma in less time, hence improving quality and safety and, in turn, better serving patients who rely on plasma-based therapies. These advantages include: On average, Rika completes one plasma collection in 35 minutes or less: Compared to previous average CSL Plasma donation timings, this might mean a nearly 30% reduction in donor donation time. It assures that no more than 200 milliliters of blood are ever removed from the donor's body. This is believed to make the donor more comfortable during the donation process and lessen the risk of red cell loss deferral. It has a sophisticated user interface that helps CSL Plasma front-line personnel operate the equipment. This milestone helps bring to life how we demonstrate innovation, collaboration, and patient-focus, part of the CSL Values that underpin our commitment to manufacturing and delivering life-saving and life-extending medicines around the world, We continue to evolve as a leading biotechnology company, investing in our core plasma business. Continued innovation that benefits our employees and plasma donors speak to how we are driven by our promise to save and improve lives around the world." CSL Chief Operating Officer Paul McKenzie. CSL Plasma will begin installing the new technology at locations in the Denver, Colorado, area in the following months. There is a critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases, CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice. We look forward to rolling out this new technology." CSL Plasma General Manager Michelle Meyer.

Read More

RESEARCH

TurtleTree and Solar Biotech enter strategic partnership

TurtleTree | August 16, 2021

Solar Biotech, led by industrial biotech expert Alex Berlin, has become a significant piece of the puzzle for sustainable food tech companies taking products to market. TurtleTree knew from the beginning that one of the biggest challenges for food tech companies was developing the technologies required to scale up bio-manufacturing processes. TurtleTree is a biotech company based in Singapore and the US. The company is focused on providing access to the best nutrients in milk using sustainable technologies. With so many food tech companies coming onto the scene, dedicated talent and resources needed to reach commercial scale are scarce. Microbes like yeast and fungi are nature's perfect tools for bio-manufacturing. Precision fermentation uses microbial hosts as cell factories to produce specific beneficial ingredients in a controlled environment without having to go through animal agriculture. What happens in the lab is just half the battle. Efficient precision fermentation and product recovery at an industrial scale demand agility, flexibility, decades of experience, unique multidisciplinary process and equipment engineering, and a well-connected network of bioprocessing and microbial biotech partners, all professionally taken care of by Solar Biotech. Many startups and VC's believe major breakthroughs in the lab will result in the real-world commercialization of bioproducts. The reality is that many projects run into years of roadblocks and scale-up challenges making commercial viability difficult. There is a major difference between traditional fermentation methods, where the microbial biomass itself is the end product, and precision fermentation, where a highly technical skillset is required to obtain the specific desired bioproduct synthesized by the microbial host. A key factor in reaching price parity with traditional food production methods is the availability of technologically advanced large-scale food-grade bioprocessing facilities, which combine precision fermentation and downstream processing lines that are customized for each player. Based on a Good Food Institute (GFI) report, available biomanufacturing facilities suitable for food precision fermentation is only 3% of the total manufacturing capacity. With the increasing demand for large-scale precision fermentation, we are already seeing the supply falling short. Alex Berlin, Solar Biotech Founder, CEO & CTO, having built his extensive experience from his time at Novozymes and other industrial biotech companies, has a track record of developing and scaling up bioproducts that were quite challenging for many others. The TurtleTree team identified this value early on, built a strong collaboration model, and made an investment in Solar Biotech. "TurtleTree's decision to back Alex Berlin and Solar Biotech's team from the early days has started to pay dividends. Our teams can focus on lab-scale R&D and go-to-market as we look to play a major role in the sustainable food supply chain, while Solar Biotech delivers the bioprocessing technologies required for production at scale," says Max Rye, co-founder and chief strategist of TurtleTree. "My team and I are passionate about not only producing the food of the future but also about making a difference in the way these bioproducts are made. Industrial Biomanufacturing at scale has not evolved significantly for decades. We are committed to making a difference, in particular, with a focus on the deployment of unique cutting edge and sustainable bioprocessing technologies. We believe solar energy and a circular economy strategy will play a major role in how we produce novel bio-processed ingredients," says Alex Berlin. About TurtleTree TurtleTree is unlocking access to the natural ingredients found in milk using a host of cell-based technologies. Together with its valued partners, TurtleTree is able to achieve resource efficiency and provide millions with access to the beneficial nutrients found in milk. We aim to transform performance nutrition, food systems, and cellular agriculture with our cell-based technology platform. About Solar Biotech Founded in 2019 by Alex Berlin, Solar Biotech brings bioproducts from benchtop to industrial bioprocessing commercial scale. Its proprietary technology uses a combination of unique technologies, skills, and experience to swiftly adapt to the needs of each bioproduct. Solar Biotech customises modular plant architectures, called BioNodes, for specific bioproducts. Solar Biotech's 100% solar-powered platform and facility help precision fermentation companies scale up their operations sustainably and at a fraction of the cost.

Read More